(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
A phase 2 trial of Bezuclastinib in systemic mastocytosis, run by Cogent Biosciences, Inc., active and no longer recruiting.
Overview
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis is a phase 2 interventional study registered as NCT05186753 by Cogent Biosciences, Inc., with 237 participants planned, started 2022-06-27 and due to reach its primary completion in 2025-05-22. Interventions recorded: Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets. Conditions listed: SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- Trial(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Shares Bezuclastinib, Cogent Biosciences, Systemic mastocytosis.
- Trial(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Shares Bezuclastinib, Cogent Biosciences.
- TargetKIT
Shares Bezuclastinib, Cogent Biosciences, Systemic mastocytosis.
- CancerGastrointestinal stromal tumour (GIST)
Shares Bezuclastinib, Systemic mastocytosis.